By: Ana Gomez

Columbus register at the CNMV its second Fund , Columbus Life Science Fund II

Columbus Life Science Fund II will complete the first closing by end of February with a target of €70M   MADRID... Read More
Columbus launches its second Fund; €70M for Biomedicine

The venture capital firm has its second fund ready to invest in health sciencie companies     Valencia, Spain, January 2019-... Read More
Viralgen Vector Core will be the Gene Therapy reference in Spain

The president of the Basque Government, Iñigo Urkullu, has chaired the inauguration ceremony of Viralgen Vector Core, the first plant of... Read More
Aura Biosciences presents Interim Phase 1b/2 Data at the ASRS Annual Meeting

  Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting CAMBRIGE. USA. July... Read More
Aura Biosciences announces Update of Clinical Safety Efficacy

  Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma CAMBRIGE. USA. June... Read More
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board

Paris, 12 June 2018- Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases today announced the…

Read More
Polypeptide Therapeutic Solutions and PMC Isochem sign business and technology collaboration agreement in the field of Cosmetic and Therapeutic Polypeptide

12 March 2018- Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services…

Read More
Aura Biosciences Completes $30 Million Series C Financing

CAMBRIDGE. 21 December 2017– Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer…

Read More
Aura Biosciences announces Interim Phase 1b/2 Data on Light-Activated AU-011 for Primary Ocular Melanoma

Light-activated viral nanoparticle for treatment of choroidal melanoma meets early study endpoints NEW ORLEANS. USA. 12 November 2017— Choroidal melanoma has... Read More
New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting

Aura Biosciences announced a late-breaking session in AAO 2017 to highlight Phase 1b Clinical Safety Study for the treatment of primary... Read More